Showing 8481-8490 of 9739 results for "".
- Allergan Again Unanimously Rejects Valeant's Revised Unsolicited Proposalhttps://practicaldermatology.com/news/20140610-allergan_again_unanimously_rejects_valeants_revised_unsolicited_proposal/2459212/Allergan has once again rejected the revised unsolicited proposal from Valeant and Pershing Square Capital Management, setting the stage for a lengthy hostile takeover battle. Allergan announced Tuesday that its board of directors, after consulting with its independent financial and legal advisors
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share and
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma L
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutation
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- NeoStrata Launches Exuviance Triple Microdermabrasionhttps://practicaldermatology.com/news/20140530-neostrata_launches_exuviance_triple_microdermabrasion/2459226/NeoStrata Company's new Exuviance Triple Microdermabrasion, described as a three-part approach to skin renewal in one single treatment, will be available nationwide in August. Exuviance Triple Microdermabrasion is formulated with professional grade crystals and Papaya Enzymes along with 1
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- mysoscience Launches Novel Pain Treatmenthttps://practicaldermatology.com/news/20140516-mysoscience_launches_novel_pain_treatment/2459238/myoscience, inc., has launched ioveradegrees, a new option to immediately block pain using the body's natural response to cold without the use of drugs or surgery. The ioveradegrees health treatment utilizes myoscience's platform technology—the Focused Cold Therapy(TM) delivery system—to precisely t